Report Detail
Global and United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Report & Forecast 2022-2028
- RnM4387723 |
- 23 February, 2022 |
- Global |
- 105 Pages |
- QYResearch |
- Medical Industry
Summary:
Market Analysis and Insights: Global and United States SERD (Selective Estrogen Receptor Degrader) Drugs Market
This report focuses on global and United States SERD (Selective Estrogen Receptor Degrader) Drugs market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global SERD (Selective Estrogen Receptor Degrader) Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, RAD1901 accounting for % of the SERD (Selective Estrogen Receptor Degrader) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, First-Line Treatment was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the SERD (Selective Estrogen Receptor Degrader) Drugs market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
Global SERD (Selective Estrogen Receptor Degrader) Drugs Scope and Market Size
SERD (Selective Estrogen Receptor Degrader) Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global SERD (Selective Estrogen Receptor Degrader) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the SERD (Selective Estrogen Receptor Degrader) Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type, the SERD (Selective Estrogen Receptor Degrader) Drugs market is segmented into
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
Segment by Application, the SERD (Selective Estrogen Receptor Degrader) Drugs market is segmented into
First-Line Treatment
Second-Line Treatment
Regional and Country-level Analysis
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Landscape and SERD (Selective Estrogen Receptor Degrader) Drugs Market Share Analysis
SERD (Selective Estrogen Receptor Degrader) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in SERD (Selective Estrogen Receptor Degrader) Drugs business, the date to enter into the SERD (Selective Estrogen Receptor Degrader) Drugs market, Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million) introduction, recent developments, etc.
The major vendors covered:
Amneal Pharmaceuticals Inc
AstraZeneca, Plc.
Dr. Reddy's Laboratories
Eli Lilly and Company
G1 Therapeutics, Inc.
Glenmark Pharmaceuticals
HBT Labs, Inc
Hoffmann-La Roche AG
InventisBio
Novartis AG
Radius Health
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zenopharm LLC.
Zentalis Pharmaceuticals
Table of Contents
1 Study Coverage
- 1.1 SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million) Introduction
- 1.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Outlook 2017 VS 2022 VS 2028
- 1.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size for the Year 2017-2028
- 1.2.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size for the Year 2017-2028
- 1.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
- 1.3.1 The Market Share of United States SERD (Selective Estrogen Receptor Degrader) Drugs in Global, 2017 VS 2022 VS 2028
- 1.3.2 The Growth Rate of SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
- 1.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market Dynamics
- 1.4.1 SERD (Selective Estrogen Receptor Degrader) Drugs Industry Trends
- 1.4.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
- 1.4.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
- 1.4.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
- 1.5 Study Objectives
- 1.6 Years Considered
2 SERD (Selective Estrogen Receptor Degrader) Drugs by Type
- 2.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment by Type
- 2.1.1 RAD1901
- 2.1.2 GDC-9545
- 2.1.3 AZD9833
- 2.1.4 SAR439859
- 2.1.5 Faslodex
- 2.1.6 Others
- 2.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017, 2022 & 2028)
- 2.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2028)
- 2.4 United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017, 2022 & 2028)
- 2.5 United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2028)
3 SERD (Selective Estrogen Receptor Degrader) Drugs by Application
- 3.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment by Application
- 3.1.1 First-Line Treatment
- 3.1.2 Second-Line Treatment
- 3.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017, 2022 & 2028)
- 3.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2028)
- 3.4 United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017, 2022 & 2028)
- 3.5 United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2028)
4 Global SERD (Selective Estrogen Receptor Degrader) Drugs Competitor Landscape by Company
- 4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Company
- 4.1.1 Top Global SERD (Selective Estrogen Receptor Degrader) Drugs Companies Ranked by Revenue (2021)
- 4.1.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Player (2017-2022)
- 4.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Concentration Ratio (CR)
- 4.2.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio (CR) (2017-2022)
- 4.2.2 Global Top 5 and Top 10 Largest Companies of SERD (Selective Estrogen Receptor Degrader) Drugs in 2021
- 4.2.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 4.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Headquarters, Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million) Type
- 4.3.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Headquarters and Area Served
- 4.3.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Companies Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million) Type
- 4.3.3 Date of International Companies Enter into SERD (Selective Estrogen Receptor Degrader) Drugs Market
- 4.4 Companies Mergers & Acquisitions, Expansion Plans
- 4.5 United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Company
- 4.5.1 Top SERD (Selective Estrogen Receptor Degrader) Drugs Players in United States, Ranked by Revenue (2021)
- 4.5.2 United States SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Players (2020, 2021 & 2022)
5 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region
- 5.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region: 2017 VS 2022 VS 2028
- 5.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2028)
- 5.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region: 2017-2022
- 5.2.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
- 6.1 North America
- 6.1.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth 2017-2028
- 6.1.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
- 6.1.3 United States
- 6.1.4 Canada
- 6.2 Asia-Pacific
- 6.2.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth 2017-2028
- 6.2.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
- 6.2.3 China
- 6.2.4 Japan
- 6.2.5 South Korea
- 6.2.6 India
- 6.2.7 Australia
- 6.2.8 China Taiwan
- 6.2.9 Indonesia
- 6.2.10 Thailand
- 6.2.11 Malaysia
- 6.3 Europe
- 6.3.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth 2017-2028
- 6.3.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
- 6.3.3 Germany
- 6.3.4 France
- 6.3.5 U.K.
- 6.3.6 Italy
- 6.3.7 Russia
- 6.4 Latin America
- 6.4.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth 2017-2028
- 6.4.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
- 6.4.3 Mexico
- 6.4.4 Brazil
- 6.4.5 Argentina
- 6.5 Middle East and Africa
- 6.5.1 Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth 2017-2028
- 6.5.2 Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
- 6.5.3 Turkey
- 6.5.4 Saudi Arabia
- 6.5.5 UAE
7 Company Profiles
- 7.1 Amneal Pharmaceuticals Inc
- 7.1.1 Amneal Pharmaceuticals Inc Company Details
- 7.1.2 Amneal Pharmaceuticals Inc Business Overview
- 7.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.1.4 Amneal Pharmaceuticals Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.1.5 Amneal Pharmaceuticals Inc Recent Development
- 7.2 AstraZeneca, Plc.
- 7.2.1 AstraZeneca, Plc. Company Details
- 7.2.2 AstraZeneca, Plc. Business Overview
- 7.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.2.4 AstraZeneca, Plc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.2.5 AstraZeneca, Plc. Recent Development
- 7.3 Dr. Reddy's Laboratories
- 7.3.1 Dr. Reddy's Laboratories Company Details
- 7.3.2 Dr. Reddy's Laboratories Business Overview
- 7.3.3 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.3.4 Dr. Reddy's Laboratories Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.3.5 Dr. Reddy's Laboratories Recent Development
- 7.4 Eli Lilly and Company
- 7.4.1 Eli Lilly and Company Company Details
- 7.4.2 Eli Lilly and Company Business Overview
- 7.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.4.4 Eli Lilly and Company Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.4.5 Eli Lilly and Company Recent Development
- 7.5 G1 Therapeutics, Inc.
- 7.5.1 G1 Therapeutics, Inc. Company Details
- 7.5.2 G1 Therapeutics, Inc. Business Overview
- 7.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.5.4 G1 Therapeutics, Inc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.5.5 G1 Therapeutics, Inc. Recent Development
- 7.6 Glenmark Pharmaceuticals
- 7.6.1 Glenmark Pharmaceuticals Company Details
- 7.6.2 Glenmark Pharmaceuticals Business Overview
- 7.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.6.4 Glenmark Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.6.5 Glenmark Pharmaceuticals Recent Development
- 7.7 HBT Labs, Inc
- 7.7.1 HBT Labs, Inc Company Details
- 7.7.2 HBT Labs, Inc Business Overview
- 7.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.7.4 HBT Labs, Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.7.5 HBT Labs, Inc Recent Development
- 7.8 Hoffmann-La Roche AG
- 7.8.1 Hoffmann-La Roche AG Company Details
- 7.8.2 Hoffmann-La Roche AG Business Overview
- 7.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.8.4 Hoffmann-La Roche AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.8.5 Hoffmann-La Roche AG Recent Development
- 7.9 InventisBio
- 7.9.1 InventisBio Company Details
- 7.9.2 InventisBio Business Overview
- 7.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.9.4 InventisBio Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.9.5 InventisBio Recent Development
- 7.10 Novartis AG
- 7.10.1 Novartis AG Company Details
- 7.10.2 Novartis AG Business Overview
- 7.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.10.4 Novartis AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.10.5 Novartis AG Recent Development
- 7.11 Radius Health
- 7.11.1 Radius Health Company Details
- 7.11.2 Radius Health Business Overview
- 7.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.11.4 Radius Health Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.11.5 Radius Health Recent Development
- 7.12 Sanofi S.A.
- 7.12.1 Sanofi S.A. Company Details
- 7.12.2 Sanofi S.A. Business Overview
- 7.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.12.4 Sanofi S.A. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.12.5 Sanofi S.A. Recent Development
- 7.13 Teva Pharmaceutical Industries Ltd.
- 7.13.1 Teva Pharmaceutical Industries Ltd. Company Details
- 7.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 7.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.13.4 Teva Pharmaceutical Industries Ltd. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.13.5 Teva Pharmaceutical Industries Ltd. Recent Development
- 7.14 Zenopharm LLC.
- 7.14.1 Zenopharm LLC. Company Details
- 7.14.2 Zenopharm LLC. Business Overview
- 7.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.14.4 Zenopharm LLC. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.14.5 Zenopharm LLC. Recent Development
- 7.15 Zentalis Pharmaceuticals
- 7.15.1 Zentalis Pharmaceuticals Company Details
- 7.15.2 Zentalis Pharmaceuticals Business Overview
- 7.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
- 7.15.4 Zentalis Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
- 7.15.5 Zentalis Pharmaceuticals Recent Development
8 Research Findings and Conclusion
9 Appendix
- 9.1 Research Methodology
- 9.1.1 Methodology/Research Approach
- 9.1.2 Data Source
- 9.2 Author Details
Summary:
Get latest Market Research Reports on SERD (Selective Estrogen Receptor Degrader) Drugs. Industry analysis & Market Report on SERD (Selective Estrogen Receptor Degrader) Drugs is a syndicated market report, published as Global and United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Report & Forecast 2022-2028. It is complete Research Study and Industry Analysis of SERD (Selective Estrogen Receptor Degrader) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
